共 58 条
[1]
Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, 2008, CA Cancer J Clin, 58, pp. 71-96, (2008)
[2]
Isaacs J.T., Role of androgens in prostatic cancer, Vitam Horm, 49, pp. 433-502, (1994)
[3]
Figg W.D., Feuer J.A., Bauer K.S., Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy, Cancer Pract, 5, pp. 258-263, (1997)
[4]
Dehm S.M., Tindall D.J., Molecular regulation of androgen action in prostate cancer, J Cell Biochem, 99, pp. 333-344, (2006)
[5]
Kohli M., Tindall D.J., New developments in the medical management of prostate cancer, Mayo Clin Proc, 85, pp. 77-86, (2010)
[6]
Labrie F., Luu-The V., Labrie C., Simard J., DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology, Front Neuroendocrinol, 22, pp. 185-212, (2001)
[7]
Amory J.K., Bremner W.J., Regulation of testicular function in men: implications for male hormonal contraceptive development, J Steroid Biochem Mol Biol, 85, pp. 357-361, (2003)
[8]
Hammond G.L., Avvakumov G.V., Muller Y.A., Structure/function analyses of human sex hormone-binding globulin: effects of zinc on steroid-binding specificity, J Steroid Biochem Mol Biol, 85, pp. 195-200, (2003)
[9]
Zhou Z.X., Lane M.V., Kemppainen J.A., French F.S., Wilson E.M., Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability, Mol Endocrinol, 9, pp. 208-218, (1995)
[10]
Tindall D.J., Rittmaster R.S., The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer, J Urol, 179, pp. 1235-1242, (2008)